CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
PremiumPress ReleasesCytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
1M ago
CytoDyn Resolves Lawsuit, Secures Payments, and Clears Debt
Premium
Company Announcements
CytoDyn Resolves Lawsuit, Secures Payments, and Clears Debt
2M ago
CytoDyn announces settlement with Amarex Clinical Research
Premium
The Fly
CytoDyn announces settlement with Amarex Clinical Research
2M ago
CytoDyn issues letter to shareholders
PremiumThe FlyCytoDyn issues letter to shareholders
4M ago
May 2024 Letter to Shareholders
Premium
Press Releases
May 2024 Letter to Shareholders
4M ago
CytoDyn to host business news update conference call
Premium
The Fly
CytoDyn to host business news update conference call
7M ago
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
PremiumPress ReleasesCytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
8M ago
CytoDyn submits revised HIV clinical trial protocol to FDA
Premium
The Fly
CytoDyn submits revised HIV clinical trial protocol to FDA
8M ago
CytoDyn Releases Regulatory FD Disclosure Information
Premium
Company Announcements
CytoDyn Releases Regulatory FD Disclosure Information
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100